These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29458117)

  • 41. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
    Ogura T; Ogata M; Akita H; Jitsuki S; Akiba L; Noda K; Hoka S; Saji M
    Neurosci Res; 2005 Mar; 51(3):299-308. PubMed ID: 15710494
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Voluntary Physical Exercise Improves Subsequent Motor and Cognitive Impairments in a Rat Model of Parkinson's Disease.
    Hsueh SC; Chen KY; Lai JH; Wu CC; Yu YW; Luo Y; Hsieh TH; Chiang YH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29419747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
    Fifel K; Dkhissi-Benyahya O; Cooper HM
    Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
    Descamps A; Rousset C; Millan MJ; Spedding M; Delagrange P; Cespuglio R
    Psychopharmacology (Berl); 2009 Jul; 205(1):93-106. PubMed ID: 19370342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Agomelatine for depression: expanding the horizons?
    Norman TR; Olver JS
    Expert Opin Pharmacother; 2019 Apr; 20(6):647-656. PubMed ID: 30759026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling.
    Tchekalarova J; Atanasova D; Kortenska L; Atanasova M; Lazarov N
    Neurobiol Dis; 2018 Jul; 115():127-144. PubMed ID: 29653194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
    Santiago RM; Barbieiro J; Lima MM; Dombrowski PA; Andreatini R; Vital MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1104-14. PubMed ID: 20547199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies into the anxiolytic actions of agomelatine in social isolation reared rats: Role of corticosterone and sex.
    Regenass W; Möller M; Harvey BH
    J Psychopharmacol; 2018 Feb; 32(2):134-145. PubMed ID: 29082818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circadian rhythm of drinking and running-wheel activity in rats with 6-hydroxydopamine lesions of the ventral tegmental area.
    Isobe Y; Nishino H
    Brain Res; 2001 Apr; 899(1-2):187-92. PubMed ID: 11311879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
    Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
    Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Like melatonin, agomelatine (S20098) increases the amplitude of oscillations of two clock outputs: melatonin and temperature rhythms.
    Castanho A; Bothorel B; Seguin L; Mocaër E; Pévet P
    Chronobiol Int; 2014 Apr; 31(3):371-81. PubMed ID: 24328729
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.
    Abuirmeileh A; Lever R; Kingsbury AE; Lees AJ; Locke IC; Knight RA; Chowdrey HS; Biggs CS; Whitton PS
    Eur J Neurosci; 2007 Jul; 26(2):417-23. PubMed ID: 17650114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model.
    Ozsoy O; Yildirim FB; Ogut E; Kaya Y; Tanriover G; Parlak H; Agar A; Aslan M
    Free Radic Res; 2015; 49(8):1004-14. PubMed ID: 25791066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treating ADHD with agomelatine.
    Niederhofer H
    J Atten Disord; 2012 May; 16(4):346-8. PubMed ID: 22491963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.
    Racagni G; Riva MA; Molteni R; Musazzi L; Calabrese F; Popoli M; Tardito D
    World J Biol Psychiatry; 2011 Dec; 12(8):574-87. PubMed ID: 21999473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switch.
    Laux G; Huttner NA;
    Int J Psychiatry Clin Pract; 2014 Jun; 18(2):86-96. PubMed ID: 24506342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
    De Berardis D; Fornaro M; Orsolini L; Iasevoli F; Tomasetti C; de Bartolomeis A; Serroni N; De Lauretis I; Girinelli G; Mazza M; Valchera A; Carano A; Vellante F; Matarazzo I; Perna G; Martinotti G; Di Giannantonio M
    CNS Spectr; 2017 Aug; 22(4):342-347. PubMed ID: 27702411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MT
    Noseda ACD; Rodrigues LS; Targa ADS; Ilkiw JL; Fagotti J; Dos Santos PD; Cecon E; Markus RP; Solimena M; Jockers R; Lima MMS
    Eur J Pharmacol; 2021 Jan; 891():173722. PubMed ID: 33159932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.